Stakeholders call for improved access to immunotherapies

Patients, clinicians, cancer support groups and industry have come together in a call for better access to immunotherapies in Australia. An advocacy document sponsored by MSD, whose product list includes pembrolizumab (Keytruda), was launched in Canberra this week. The New Wave of Immunotherapy Cancer Medicines –The Untapped Potential for Australians has called for a tumour-agnostic ...